32nd week of 2013 patent applcation highlights part 48 |
Patent application number | Title | Published |
20130203627 | System and Method For Detecting Multiple Molecules in One Assay - A rapid diagnostic system that delivers a panel of serologic assay results using a small amount of blood, serum, or plasma is described. The system includes a disposable cartridge, including an integral lens portion coupled to a planar waveguide, and a reader instrument, based on planar waveguide imaging technology. The cartridge incorporates a microarray of recombinant antigens and antibody controls in a fluidic channel, providing multiple parallel fluorescence assay results for a single sample. | 2013-08-08 |
20130203628 | SET OF OLIGONUCLEOTIDE PROBES AS WELL AS METHODS AND USES THERETO - The present disclosure relates to a set of at least 100 single-stranded oligonucleotide probes directed against (or complementary to) portions of a genomic target sequence of interest. The present disclosure also relates to a method of detecting a genomic target sequence of interest using the set of oligonucleotide probes and a method of generating the set of oligonucleotide probes. Further, the present disclosure relates to a kit comprising the set of oligonucleotide probes and at least one further component. | 2013-08-08 |
20130203629 | METHOD FOR FUNCTIONALIZING SURFACES FOR ANALYTE DETECTION - The invention relates to a device for detecting analytes, including a plastic substrate at least partially covered by bonding polymers attached to the substrate in a non-covalent manner, said bonding polymers comprising a polysaccharide backbone provided with aromatic groupings and carboxylic acid groupings. | 2013-08-08 |
20130203630 | MODIFIED PEPTIDE DISPLAY - The invention provides a replicable genetic package displaying a cyclic peptide having at least one intramolecular bond between amino acid side chains. Also provided are a method of preparing such a genetic package displaying cyclic peptides having at least one intramolecular bond. Further provided is a library of replicable genetic packages displaying cyclic peptides each having at least one intramolecular cyclic bond between amino acid side chains; and a method of producing such a library. | 2013-08-08 |
20130203631 | FRAMELESS MULTIPLEXED MICROARRAYS - The present invention relates to novel methods for the quantitative detection of molecules in an array. In particular, the present invention relates to methods and apparatuses for producing a frameless array. In another embodiment, the present invention relates to a composition comprising nitrocellulose that is useful of producing a frameless array. In another embodiment, the present invention relates to a method for detecting a molecular interaction. In yet another embodiment, the present invention relates to kits useful for practicing the methods and apparatuses of the present invention. The present invention provides improved methods and apparatuses for the high throughput analysis of molecular interactions and quantitative detection. | 2013-08-08 |
20130203632 | DETECTION OF NUCLEIC ACIDS BY TARGET-SPECIFIC HYBRID CAPTURE METHOD - Target-specific hybrid capture (TSHC) provides a nucleic acid detection method that is not only rapid and sensitive, but is also highly specific and capable of discriminating highly homologous nucleic acid target sequences. The method produces DNA:RNA hybrids which can be detected by a variety of methods. | 2013-08-08 |
20130203633 | Plant Chimeric Binding Polypeptides For Universal Molecular Recognition - Libraries of nucleic acids encoding chimeric binding polypeptides based on plant scaffold polypeptide sequences. Also described are methods for generating the libraries. | 2013-08-08 |
20130203634 | INTEGRATED ANALYSIS SYSTEM - The invention provides systems, devices, methods, and kits for performing an integrated analysis. The integrated analysis can include sample processing, library construction, amplification, and sequencing. The integrated analysis can be performed within one or more modules that are fluidically connected to each other. The one or more modules can be controlled and/or automated by a computer. The integrated analysis can be performed on a tissue sample, a clinical sample, or an environmental sample. The integrated analysis system can have a compact format and return results within a designated period of time. | 2013-08-08 |
20130203635 | NUCLEIC ACID LIGATION METHOD - Methods and kits for covalently joining a 3′ nucleic acid fragment having a 5′-hydroxyl terminus to a 5′ nucleic acid fragment having a 3′-phosphate terminus are disclosed. The methods include the step of contacting the 3′-phosphate terminus of a first nucleic acid molecule and the 5′-hydroxyl terminus of a second nucleic acid molecule with an isolated 2′,3′-cyclic phosphate RNA ligase (RtcB) and a purine triphosphate in the presence of manganese (II) ion, whereby the 3′-phosphate terminus of the first nucleic acid molecule and the 5′-hydroxyl terminus of the second nucleic acid molecule are covalently joined. | 2013-08-08 |
20130203636 | Water-Based Mud Lubricant Using Fatty Acid Polyamine Salts and Fatty Acid Esters - Water-based drilling mud lubricants using a blend of fatty acid polyamine salts and fatty acid esters give synergistically better lubricity results than either component used separately. For example, the blends with different ratios of fatty acid diethylenetriamine salt and fatty acid methyl ester demonstrate much better lubricity in water-based drilling fluids than those where only fatty acid diethylene-triamine salt or fatty acid methyl ester are separately used. The amines in fatty acid amine salt might also include other polyamines, such as butanediamine pentamethylenediamine, spermidine, spermine, propylene diamine and propylene polyamines. The fatty acid esters might also include fatty acid ethyl ester, fatty acid glycerol ester and fatty acid trimethylolpropane ester. The carbon numbers of the fatty acids used to make the components in the lubricant blend may range from C4 to C28. | 2013-08-08 |
20130203637 | METHOD OF DELAYING CROSSLINKING IN WELL TREATMENT OPERATION - Crosslinking of a crosslinkable viscosifying agent and a crosslinking agent may be delayed in a well treatment fluid by incorporated within the fluid a glutamic-N,N-diacetic acid salt, such as a glutamic-N,N-diacetic acid sodium salt like tetrasodium glutamate diacetate. The crosslinking agent may be a zirconium containing crosslinking agent like zirconium (IV) acetyl acetonate. The viscosifying agent may be guar or a guar derivative such as carboxyalkyl guars and hydroxyalkylated guars like carboxymethyl guar, hydroxypropyl guar, hydroxyethyl guar, hydroxybutyl guar and carboxymethylhydroxypropyl guar. | 2013-08-08 |
20130203638 | Lubricating Composition Containing a Carboxylic Functionalised Polymer - The invention provides a lubricating composition comprising an oil of lubricating viscosity and an amine-functionalised additive, wherein the amine-functionalised additive is derived from an amine having at least 3 aromatic groups, at least one —NH2 functional group, and at least 2 secondary or tertiary amino groups. The invention further provides for the additive to have improved thermal and oxidative stability modifying properties. The lubricating composition may include circulating oils, turbine oils, hydraulic fluids, transformer oils and greases as well as others that require good oxidation stability and good rust inhibition properties. | 2013-08-08 |
20130203639 | Overbased Alkylated Arylalkyl Sulfonates - An overbased alkylated arylalkyl sulfonate is easy to prepare and is useful as a detergent in various lubricant applications. | 2013-08-08 |
20130203640 | POLYMER COMPOSITIONS HAVING IMPROVED PROPERTIES AS VISCOSITY INDEX IMPROVERS AND USE THEREOF IN LUBRICATING OILS - Polymer compositions for use as viscosity modifiers comprising at least two ethylene-based copolymer components are provided. The polymer composition comprises (a) a first ethylene-α-olefin copolymer and (b) a second ethylene-α-olefin copolymer. The first ethylene-α-olefin copolymer (a) has an ethylene content from about 60 to about 80 wt % and the second ethylene-α-olefin copolymer (b) has an ethylene content of less than about 60 wt %. The first ethylene-α-olefin copolymer (a) has a Melt Flow Rate Ratio (MFRR), defined as the ratio of the MFR measured at 230° C./21.6 kg and at 230° C./2.16 kg, of greater than 30 and optionally also has a Melt Flow Rate (MFR) of at least about 1.5 g/10 min, measured by ASTM D 1238 condition L (230° C./2.16 kg). The present disclosure is also directed to lubricant compositions comprising a lubricating basestock and a polymer composition of the present disclosure and is further directed to reducing gelation in the lubricant compositions. | 2013-08-08 |
20130203641 | Process for the Production of Polymeric Compositions Useful as Oil Modifiers - Provided are processes for making polymer compositions, especially those with reduced or no gel formation in lubricating oils as identified by rheological and visual gel tests and which are useful as viscosity modifiers. The processes described herein aim to achieve this objective by adjusting the concentrations of the hydrogen feed(s) in the first and/or second polymerization reaction zones, preferably such that (a) the hydrogen feed concentration in the first polymerization reaction zone is 0.0-1.0 wt %, based on total weight of feed(s) of hydrogen, ethylene monomer, α-olefin comonomer, and solvent into the first polymerization reaction zone, and/or (b) the hydrogen feed concentration in the second polymerization reaction zone is 0.0-0.5 wt %, based on total weight of feed(s) of hydrogen, ethylene monomer, α-olefin comonomer, and solvent into the second polymerization reaction zone. | 2013-08-08 |
20130203642 | MICROCAPSULE CONTAINING DETERGENT OR CLEANING AGENT - The invention relates to detergents or cleaning agents which comprise capsules that are low in formaldehydes and/or free from formaldehyde, are storage stable and thus prevent a contamination of the detergent or cleaning agent with formaldehyde, comprising microcapsules, the capsule wall of which contains a resin which is obtained by reacting at least one aromatic alcohol or ether or derivative thereof and at least one aldehydic component which comprises at least two C-atoms per molecule, and optionally at least one (meth)acrylate-polymer, and builders and/or surfactants. Said detergent or cleaning agents enable, during application, a targeted and durable release of liquid active agents, such as, in particular scents, to the treated objects. | 2013-08-08 |
20130203643 | CLEANING AGENT FOR SEMICONDUCTOR PROVIDED WITH METAL WIRING - A cleaning agent for a microelectronic device provided with metal wiring, which has an excellent ability to remove polishing particle residues derived from a polishing agent and an excellent ability to remove metallic residues on an insulating film, and has excellent anticorrosiveness to the metal wiring. The cleaning agent is used at a step subsequent to chemical mechanical polishing in a manufacturing process of a microelectronic device in which a metal wiring, e.g., copper or tungsten, is formed. | 2013-08-08 |
20130203644 | COMPOSITIONS AND METHODS FOR SURFACE TREATMENT WITH LIPASES - Methods and compositions for treating textiles and hard surfaces with compositions having specific lipases are described. The compositions have increased stability to oxidative degradation in particular due to bleach catalysts. | 2013-08-08 |
20130203645 | METHOD OF ENHANCING MUSCLE PROTEIN SYNTHESIS - The present invention relates to a method of enhancing muscle protein synthesis following physical exertion comprising administering to a human a composition comprising protein or essential amino acids and carbohydrates 30 minutes or less prior to, during, or within 30 minutes of running repeated sprints. Further, the invention relates to a program for enhancing muscle adaptation resulting from repeated sprints training. | 2013-08-08 |
20130203646 | SUPPORTING ACTIVITIES OF DAILY LIVING - The invention provides a method for supporting operational activities in daily living by providing a combination of (a) long-chain polyunsaturated fatty acids, particularly DHA and/or EPA, and (b) nucleosides or nucleotides, particularly uridine or its equivalent. The operational activities comprise eating; walking; toileting; bathing; grooming; dressing; use of communication equipment; making conversations; keeping appointments; use of household appliances; cleaning dishes; preparation of meal or drink; writing; reading; independent housekeeping; transportation and shopping. | 2013-08-08 |
20130203647 | DELIVERY OF HYDROPHILIC PEPTIDES - A composition comprises nanofibres for the delivery of a peptide across the blood brain barrier in a method of therapy of the human or animal body, wherein the nanofibres comprise a peptide conjugated to a lipophilic group. Further, a compound comprises a Dalargin or a derivative having one or more substituted, deleted or inserted aminoacyl units, and, conjugated to an aminoacyl group preferably via a side chain, a lipophilic group, optionally via a linker. | 2013-08-08 |
20130203648 | Preparation of Recombinant Human Plasma Phospholipid Transfer Protein (PLTP) From the Milk of Transgenic Animals - The invention relates to obtaining a preparation of recombinant human PLTP from the milk of a transgenic animal containing in its genome one or more copies of a transgene comprising a polynucleotide coding for human PTLP, placed under transcriptional control of a promoter permitting its specific expression in the cells of the mammary glands of said animal. The recombinant human PLTP preparation obtained can be used in the prevention or treatment of septic shock. | 2013-08-08 |
20130203649 | INHIBITORS OF TLR SIGNALING BY TARGETING TIR DOMAIN INTERFACES - TIR-domain decoy peptides and TIR domain peptides are disclosed, as well as methods of using the peptides in the regulation of toll-like receptor (TLR) activation and signaling. | 2013-08-08 |
20130203650 | POLYPEPTIDES DERIVED FROM ALPHA-1 ANTITRYPSIN AND METHODS OF USE THEREOF - The present invention relates to isolated polypeptides comprising the amino acid sequence of residues 378-413 of | 2013-08-08 |
20130203651 | PHARMACEUTICAL COMPOSITION FOR TREATING A METABOLIC SYNDROME - The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. | 2013-08-08 |
20130203652 | DIFFOCINS AND METHODS OF USE THEREOF - This disclosure relates to the discovery and isolation of the entire cluster of genes encoding R-type high molecular weight bacteriocins that specifically kill | 2013-08-08 |
20130203653 | BACTERIAL-DERIVED BLIS FOR TREATMENT OF ACNE - This invention relates to a treatment of acne. Specifically, the invention is directed to the use of bacteriocin-like inhibitory substances (BLIS), isolated from | 2013-08-08 |
20130203654 | NOVEL CYCLIC PEPTIDE COMPOUND, METHOD FOR PRODUCING SAME, ANTI-INFECTIVE AGENT, ANTIBIOTIC-CONTAINING FRACTION, ANTIBIOTIC, METHOD FOR PRODUCING ANTIBIOTIC, ANTIBIOTIC-PRODUCING MICROORGANISM, AND ANTIBIOTIC PRODUCED BY SAME - Provided are: a novel compound having a structure different from that of existing drugs; a novel microorganism capable of producing the novel compound; and further; a novel compound effective to a multiple-drug-resistant bacterium. To provide a novel compound having a high therapeutic effect which can be expected to have a low hurdle for practical realization by selecting an intended compound from many candidate compounds based not only on an antibacterial activity but also on evaluation including a therapeutic effect, a cyclic peptide compound shown by the following formula (1) or a pharmaceutically allowable salt thereof and a microorganism with Accession No. NITE BP-870 or a microorganism mutated naturally or artificially therefrom are provided. | 2013-08-08 |
20130203655 | METHODS FOR PREVENTING OR TREATING VIRAL INFECTION - The present invention provides methods to prevent or treat flavivirus infection, and assays for identifying agents which treat flavivirus infection. The present invention also provides compositions for preventing flavivirus infection and a kit for screening an agent that prevents or treats viral infection. | 2013-08-08 |
20130203656 | INHIBITORS OF HCV NS5A - Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C. | 2013-08-08 |
20130203657 | USE OF VIPAB IN COMBINATION WITH CRY1CA FOR MANAGEMENT OF RESISTANT INSECTS - The subject invention includes methods and plants for controlling fall army worm lepidopteran insects, said plants comprising a V1p3Ab insecticidal protein and a Cry1Ca insecticidal protein, and various combinations of other proteins comprising this pair of proteins, to delay or prevent development of resistance by the insects. | 2013-08-08 |
20130203658 | Low-Caloric High-Protein Nutritional Composition for the Stimulation of Muscle Protein Synthesis - The present invention relates to the use of a low-caloric high-protein nutritional composition for use in the prevention or treatment of a disease or condition in a mammal, which involves muscle decline, as well as to specific low-caloric high-protein nutritional compositions for stimulating muscle protein synthesis in a mammal. In particular, the invention relates to the use of a nutritional composition comprising per 100 kcal: (i) at least about 12 g of proteinaceous matter which comprises at least about 80 weight % of whey protein, relative to the total proteinaceous matter, and which comprises at least about 11 weight % of leucine, relative to the total proteinaceous matter, of which at least about 20 weight % is in a free form, relative to the total leucine, (ii) a source of fat and a source of digestible carbohydrates, for the prevention or treatment of a disease or condition which involves muscle decline in a mammal, especially an elderly mammal, wherein the nutritional composition is administered as 1 to 2 servings daily, each serving comprising between 80 and 200 kcal. | 2013-08-08 |
20130203659 | GLP-1 COMPOUNDS - GLP-1 compounds comprising GLP-1 analogs and methods of using the GLP-1 compounds for treating metabolic disorders, enhancing insulin expression, and promoting insulin secretion in a patient are provided. | 2013-08-08 |
20130203660 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS - Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR). | 2013-08-08 |
20130203661 | HIGHLY SOLUBLE LEPTINS - The disclosure provides chimeric polypeptides and nucleic acid molecules encoding chimeric polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease. | 2013-08-08 |
20130203662 | Mini-Hepcidin Peptides and Methods of Using Thereof - Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof. | 2013-08-08 |
20130203663 | TUBE FEED FORMULATIONS AND METHODS FOR USING SAME - Nutritional compositions that mimic whole foods and methods of using the nutritional compositions are provided. The nutritional compositions may include an increased number and variety of fruits and vegetables, an increased variety of macronutrient sources and an increased amount of other components that are found in whole foods. The nutritional compositions may also include ethnicity-specific meals and organic ingredients and provide emotional appeal to the patient and/or the patient's caregiver. Methods of administering such nutritional compositions to patients in need of same are also provided. | 2013-08-08 |
20130203664 | HYPOCALORIC, HIGH PROTEIN NUTRITIONAL COMPOSITIONS AND METHODS OF USING SAME - Nutritional compositions having reduced amounts of calories and high amounts of protein and methods of making and using the nutritional compositions are provided. The nutritional compositions may include a processed whole food component, a high amount of protein, and a reduced amount of calories in order to provide a patient with a pH-balanced formulation that includes the benefits of food bioactives beyond essential macro- and micronutrients without providing excessive energy. Methods of administering such nutritional compositions to patients in need of improved bone, muscle, neurological, immune, and/or overall health are also provided. | 2013-08-08 |
20130203665 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR - Single chain insulin analogs are provided having high potency and specificity for the insulin receptor. As disclosed herein optimally sized linking moieties can be used to link human insulin A and B chains, or analogs or derivatives thereof, wherein the carboxy terminus of the B25 amino acid of the B chain is linked to the amino terminus of the A1 amino acid of the A chain via the intervening linking moiety. In on embodiment the linking moiety comprises a polyethylene glycol of 6-16 monomer units and in an alternative embodiment the linking moiety comprises a non-native amino acid sequence derived form the IGF-1 C-peptide and comprising at least 8 amino acids and no more than 12 amino acid in length. Also disclosed are prodrug and conjugate derivatives of the single chain insulin analogs. | 2013-08-08 |
20130203666 | PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN DIABETES TYPE 2 PATIENTS - The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients. | 2013-08-08 |
20130203667 | Methods and Compositions for Promoting Organ Development - Compositions and methods are provided for promoting organ development in warm blooded animals, and in particular in certain aspects a premature infant or foetus. Compositions and methods are also provided for the administration of at least one colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof, or otherwise, at least one nucleic acid molecule encoding colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof. | 2013-08-08 |
20130203668 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIPLATELET AGENTS AND AN ERYTHROPOIESIS STIMULATING AGENT - A composition comprising suitable anti-platelet agent/agents and the erythropoiesis stimulating agent for the treatment and improvement of kidney function is described. The combination also provides treatment and improvement in cardiovascular and bleeding related disorders. This composition shows synergistic interaction and significantly reduces the kidney damage caused by administration of erythropoiesis stimulating agents. Moreover the present composition normalizes the platelet reactivity and bleeding time in patients with chronic kidney disease. | 2013-08-08 |
20130203669 | MEDICAMENT - Analysis of a goat serum product with many therapeutic effects is described. The product is identified as containing proopiomelanocortin (POMC) and Corticotropin releasing factor (CRF) peptides, as well as breakdown products of these peptides. We describe methods of treatment of diseases including cancers, multiple sclerosis, and neural disorders using these peptides and their products, as well as medicaments including such peptides and methods of producing the peptides. | 2013-08-08 |
20130203670 | Therapy For Vitiligo - The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo. | 2013-08-08 |
20130203672 | Novel Glucagon Like Peptide Analogs, Composition, and Method of Use - The present invention relates to novel analogs of glucagon like peptide and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes. In particular, these peptide derivatives have a peptide mimic linker and provides long duration of action for the treatment of diabetes and other insulinotropic peptide related diseases, gastrointestinal function and activities associated with glucagon levels. | 2013-08-08 |
20130203673 | GLUCAGON-LIKE PEPTIDE-2 ANALOGS - Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described. | 2013-08-08 |
20130203674 | PROCESS FOR PRODUCTION OF BIVALIRUDIN - The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp | 2013-08-08 |
20130203675 | ASYMMETRIC BIOFUNCTIONAL SILYL MONOMERS AND PARTICLES THEREOF AS PRODRUGS AND DELIVERY VEHICLES FOR PHARMACEUTICAL, CHEMICAL AND BIOLOGICAL AGENTS - Asymmetric bifunctional silyl (ABS) monomers comprising covalently linked pharmaceutical, chemical and biological agents are described. These agents can also be covalently bound via the silyl group to delivery vehicles for delivering the agents to desired targets or areas. Also described are delivery vehicles which contain ABS monomers comprising covalently linked agents and to vehicles that are covalently linked to the ABS monomers. The silyl modifications described herein can modify properties of the agents and vehicles, thereby providing desired solubility, stability, hydrophobicity and targeting. | 2013-08-08 |
20130203676 | MU-CONOTOXIN PEPTIDES AND USE THEREOF AS A LOCAL ANESTHETIC - The present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and/or variants thereof. The invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic. | 2013-08-08 |
20130203677 | BIOACTIVE PEPTIDE - The present invention provides a pharmaceutical or a food that comprises, as an active ingredient, at least one peptide selected from the group consisting of Val-Tyr-Leu-Pro-Arg, Tyr-Leu-Pro-Arg, and Leu-Pro-Arg, or an analog thereof. | 2013-08-08 |
20130203678 | COMPSTATIN ANALOGS FOR TREATMENT OF NEUROPATHIC PAIN - In some aspects, the present invention provides methods of treating a subject in need of treatment for neuropathic pain, the method comprising administering a compstatin analog to the subject. In some embodiments, the compstatin analog is administered parenterally, e.g., intravenously. | 2013-08-08 |
20130203679 | IMMUNOREGULATORY PEPTIDES AND METHODS OF USE - Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-α secretion through interaction with toll-like receptors. Experiments are described illustrating the efficacy of the compounds in treating otitis media | 2013-08-08 |
20130203680 | FOLATE CONJUGATES FOR TREATING INFLAMMATION OF THE EYE - The present invention relates to methods of use of folate conjugates for treating inflammatory diseases of the eye, to folate conjugates for use in treating inflammatory diseases of the eye, and to folate conjugates for use in the manufacture of a medicament for treating inflammatory diseases of the eye. More particularly, the invention is directed to the use of folate linked to one or more anti-inflammatory agents for each of the above-described uses. | 2013-08-08 |
20130203681 | Macrocyclic Compounds Useful as Inhibitors of Histone Deacetylases - The present invention provides a novel macrocyclic compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. | 2013-08-08 |
20130203682 | RANK LIGAND POLYPEPTIDES - Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL. | 2013-08-08 |
20130203683 | IMMUNOREGULATORY PEPTIDES AND METHODS OF USE - Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-α secretion through interaction with toll-like receptors. Experiments are described illustrating the efficacy of the compounds in treating otitis media | 2013-08-08 |
20130203684 | METHOD OF ACHIEVING A THYMOSIN BETA 4 CONCENTRATION IN A HUMAN PATIENT - The present invention provides embodiments which involve methods of providing a predetermined concentration of thymosin beta 4 (TB4) at a predetermined time, t, in a body portion of a live human patient. The methods can include determining a thymosin beta 4 treatment dosage (D) using Formula I: C=(A)D.t | 2013-08-08 |
20130203685 | PROTEASE TARGETING AGENTS - Peptides having the ability to block the activity of acyl-aminoacid releasing enzymes such as AARE or APEH are disclosed. Derivatives of the peptides include oligomers or multimers of the peptide linked to a common scaffold moiety such as a tri-functional amino acid and peptides linked to PEG and fatty acids. Pharmaceutical compositions that include the peptide are also disclosed and can be used to treat various diseases such as cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases and urological diseases. | 2013-08-08 |
20130203686 | AZAPEPTIDES AS CD36 BINDING COMPOUNDS - An azapeptide compound of Formula I: | 2013-08-08 |
20130203687 | NOVEL LIPID TRIPEPTIDE-BASED HYDROGELATOR AND HYDROGEL - A hydrogel that includes an aqueous solution or an alcohol aqueous solution, and a hydrogelator containing a lipid peptide represented by Formula (1), or a pharmaceutically usable salt thereof. In Formula (1), R | 2013-08-08 |
20130203688 | SUGAR PLANT DERIVED BY-PRODUCTS AND METHODS OF PRODUCTION THEREOF - The present document describes a nutraceutical or cosmeceutical composition for the prophylaxis of an ailment comprising a therapeutically effective amount of a sugar plant syrup filtration residue in association with a pharmaceutically acceptable carrier. The present document also describes a nutraceutical or cosmeceutical composition for improving health condition of skin. The present document describes a method of producing a sugar plant syrup-derived product; wherein the improvement is characterized in the step of: collecting a sugar plant syrup residue during the production of sugar or syrup to produce a syrup-derived by-product. | 2013-08-08 |
20130203689 | CHEMICAL DERIVATIVES OF JASMONATE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to novel jasmonate derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for prevention and treatment of cancers. | 2013-08-08 |
20130203690 | PDE III INHIBITORS FOR TREATMENT OF ASYMPTOMATIC HEART FAILURE - Phosphodiesterase type III (PDE III) inhibitor or a “Ca | 2013-08-08 |
20130203691 | STABLE INSECTICIDE COMPOSITIONS AND METHODS FOR PRODUCING SAME - Insect controlling compositions including an N-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximine compound exhibiting increased stability, along with methods for preparing same, are disclosed. | 2013-08-08 |
20130203692 | PARASITICIDAL ORAL VETERINARY COMPOSITIONS COMPRISING SYSTEMICALLY-ACTING ACTIVE AGENTS, METHODS AND USES THEREOF - This invention relates to oral veterinary compositions for combating ectoparasites and endoparasites in animals, comprising at least one systemically-acting active agent in combination with a pharmaceutically acceptable carrier. This invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof. | 2013-08-08 |
20130203693 | 4,6-SUBSTITUTED 2,5-DIDEOXYSTREPTAMINE AMINOGLYCOSIDE ANTIBIOTICS - Aminoglycoside antibiotics of the formula | 2013-08-08 |
20130203694 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS - Rel proteins as a novel therapeutic agent for treating bacterial threats. More specifically, a novel class of compounds of Formula (I) as disclosed herein which possess anti-bacterial activity and which inhibit RelA, RelSeq or RelSpo synthetic activity or bacterial spore formation. Also, pharmaceutical compositions of such compounds and a method of combating bacteria, or treating bacterial infections, by administering to a subject in need thereof such compounds or pharmaceutical compositions. | 2013-08-08 |
20130203695 | HYPERSULFATED DISACCHARIDES TO TREAT ELASTASE RELATED DISORDERS - Hypersulfated disaccharides of formula I and other hypersulfated disaccharides disclosed herein are used to treat diseases or conditions associated with human neutrophil elastase imbalances. The disaccharides and/or intermediates useful to prepare such compounds are prepared from heparin. The diseases and conditions which are treated with a compound of formula I include chronic obstructive pulmonary disorder (COPD) and cystic fibrosis (CF). The formulations are delivered to the lungs in an aerosol formulation or dry powder means or via nebulization. Oral forms are also suitable. | 2013-08-08 |
20130203696 | DERMAL FILLER COMPOSITIONS FOR FINE LINE TREATMENT - The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions which are particularly advantageous for correction of fine lines in the face. | 2013-08-08 |
20130203697 | CROSSLINKED HYALURONIC ACID COMPOSITION AND SELF-CROSSLINKING HYALURONIC ACID PARTICLES - The present invention provides a crosslinked hyaluronic acid composition including self-crosslinking hyaluronic acid particles having an equilibrium swelling capacity of 3-fold to 10-fold, and an aqueous solvent, wherein a dry weight of the self-crosslinking hyaluronic acid particles based on the total volume of the crosslinked hyaluronic acid composition is 3 w/v % to 8 w/v %. | 2013-08-08 |
20130203698 | AQUEOUS IRON CARBOHYDRATE COMPLEXES, THEIR PRODUCTION AND MEDICAMENTS CONTAINING THEM - Water soluble Iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and medicament for the treatment and prophylaxis of iron deficiency conditions. | 2013-08-08 |
20130203699 | METHOD FOR INHIBITING THE GROWTH OF MICROBES WITH A MODIFIED CELLULOSE FIBER - A method of inhibiting the growth of bacteria in an absorbent device by using kraft pulp fiber subjected to an acidic, catalyzed peroxide treatment process incorporated into a single stage of a multi-stage bleaching process. | 2013-08-08 |
20130203700 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein. | 2013-08-08 |
20130203701 | COMPOSITIONS CONTAINING OMEGA-3 OIL AND USES THEREOF - The invention provides pharmaceutical compositions containing omega-3 oil and a non-hydrophilic co-solvent that have an increased absorption rate. The pharmaceutical compositions may further contain one or more pharmaceutical organic molecules. The invention further provides kits containing these pharmaceutical compositions, methods for formulating pharmaceutical compositions containing omega-3 oil, and methods for decreasing the likelihood of developing cardiovascular disease, decreasing triglyceride or LDL cholesterol levels, decreasing pain or inflammation, treating diabetes, chronic pulmonary diseases, or irritable bowel syndrome, decreasing symptoms of an autoimmune disease or allergic conditions. | 2013-08-08 |
20130203702 | HETEROCYCLYL-PYRIDINYL-BASED BIPHOSPHONIC ACID, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF - The present invention relates to novel compounds, compositions containing same and methods for inhibiting human farnesyl pyrophosphate synthase or for the treatment or prevention of disease conditions using said compounds; | 2013-08-08 |
20130203703 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS - The present invention relates to compounds which are 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides, their thieno-pyridone analogs, and prodrugs thereof. This invention specifically relates to such derivatives containing an N-hydrogen in the carboxanilide moiety and which exhibit modulating activity towards the aromatic hydrocarbon receptor (AhR), and, specifically, also to prodrugs thereof. The present invention also relates to use of said compounds as a medicament, and for the treatment of cancer, autoimmune disorders and other disorders with an immunological component, and a pharmaceutical composition comprising one or more of said compounds and a method of treatment. | 2013-08-08 |
20130203704 | COMPOUNDS FOR THE TREATMENT OF ADDICTION - Disclosed are novel compounds having the structure of Formula (I): | 2013-08-08 |
20130203705 | Pyrazole Compounds Acting Against Allergic, Immune and Inflammatory Conditions - The present invention relates to a pyrazole amide derivative, pharmaceutical compositions containing this compound and to its use in therapy. | 2013-08-08 |
20130203706 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS - A compound is represented by Structural Formula (I): | 2013-08-08 |
20130203707 | Oxidized Lipid Compounds and Uses Thereof - Novel oxidized lipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions. | 2013-08-08 |
20130203708 | ACTIVE SUBSTANCE COMBINATIONS THAT HAVE NEMATICIDAL, INSECTICIDAL, AND FUNGICIDAL PROPERTIES AND ARE BASED ON TRIFLUOROBUTENYL COMPOUNDS - Disclosed are novel active substance combinations comprising specific heterocyclic trifluorobutenyls and previously known fungicidal agents. Said active substance combinations have a very good synergistic fungicidal, nematicidal, insecticidal, and/or acaricidal effect. | 2013-08-08 |
20130203709 | ACYLSULFONAMIDES AND PROCESSES FOR PRODUCING THE SAME - The present disclosure relates to acylsulfonamides and processes for their preparation. The processes involve a target-guided synthesis approach, whereby a thioacid and a sulfonyl azide are reacted in the presence of a biological target protein, a Bcl-2 family protein, to form the acylsulfonamide. | 2013-08-08 |
20130203710 | ANTIVIRAL COMPOUND AND COX-2 INHIBITOR COMBINATION THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES, INCLUDING COMBINATION OF FAMCICLOVIR AND CELECOXIB - The present invention relates to methods of treating fibromyalgia, by administering a therapeutically-effective combination of an antiviral component and a COX-2 inhibitor component. The invention is further related to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound famciclovir and a therapeutically-effective amount of the COX-2 inhibitor celecoxib. The invention is also related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of famciclovir and celecoxib. | 2013-08-08 |
20130203711 | NOVEL HERBAL OIL FOR CONTROLLING BLOOD SUGAR WITHOUT RISK OF HYPOGLYCEMEA - The invention relates to a herbal oil, for controlling blood sugar without risk of hypoglycemia, comprising of the step of (i)
| 2013-08-08 |
20130203712 | METHODS FOR INHIBITING MUSCLE ATROPHY - In one aspect, the invention relates methods for inhibiting or preventing muscle atrophy or increasing muscle mass by providing to a subject in need thereof an effective amount of ursolic acid, a derivative thereof, or an analog of the ursane scaffold. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2013-08-08 |
20130203713 | POLYMERIC BIOMATERIALS DERIVED FROM PHENOLIC MONOMERS AND THEIR MEDICAL USES - The present invention provides new classes of phenol compounds, including those derived from tyrosol and analogues, useful as monomers for preparation of biocompatible polymers, and biocompatible polymers prepared from these monomeric phenol compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric phenol compounds and biocompatible polymers. | 2013-08-08 |
20130203714 | CHEMICAL COMPOUNDS - 643 - The invention concerns bicyclic compounds of Formula I | 2013-08-08 |
20130203715 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS - Methods are described for treating or preventing a respiratory infection by administering an effective amount of a TRP channel agonist. | 2013-08-08 |
20130203716 | Inhaled Combination Therapy - There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery. | 2013-08-08 |
20130203717 | Process for Particle Processing of Active Pharmaceutical Ingredients - A process for reducing the particle size of an active pharmaceutical ingredient (API) while maintaining its polymorphic form, comprises the step of processing the active pharmaceutical ingredient by cavitation at elevated pressure. The process preferably comprises the step of isolating the processed active ingredient in the form of powder, wherein the isolation step comprises filtration or spray drying. Particles produced by the process of the invention typically have a span value of less than 2.5. | 2013-08-08 |
20130203718 | PROGESTERONE RECEPTOR ANTAGONISTS AND USES THEREOF - The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies. | 2013-08-08 |
20130203719 | USE OF SPIRONOLACTONE-BASED COMPOSITION THAT EXHIBITS AN INHIBITORY ACTION ON T-LYMPHOCYTE ACTIVATION WHICH IS USEFULE FOR PREVENTING AND/OR TREATING MULTIPLE SCLEROSIS - The present invention relates to the use of spironolactone for the preparation of a pharmaceutical composition intended for preventing and/or treating multiple sclerosis. Alternatively, the invention relates to the use of spironolactone directly in T-lymphocytes or dendritic cells obtained from a blood sample taken from a patient and then injected back into the circulation. Therefore, the present invention relates to the use of a composition comprising spironolactone that can be used in the treatment of multiple sclerosis, which covers the administration of spironolactone directly or lymphocytes pre-treated with spironolactone, or dendritic cells to individuals requiring such treatment. Spironolactone is an orally administered drug that is less expensive than many of the treatments available for MS and, furthermore, has the advantage of being a known compound already used in humans for extended periods and therefore the adverse effects thereof have been described in clinical studies. | 2013-08-08 |
20130203720 | TESTOSTERONE GEL AND METHOD OF USE - The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use. | 2013-08-08 |
20130203721 | TASTE-MASKED POWDER FOR SUSPENSION COMPOSITIONS OF METHYLPREDNISOLONE - A dry taste masked powder composition comprising a steroid or its salts or derivatives and pharmaceutically acceptable excipients. The taste-masked powder may be used for suspension compositions suitable for use as a liquid suspension for children and elderly patients. | 2013-08-08 |
20130203722 | ESTRIOL THERAPY FOR AUTOIMMUNE AND NEURODEGENERATIVE DISEASE AND DISORDERS - The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases) and more particularly. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these Th1-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period. | 2013-08-08 |
20130203723 | Preparation for Improving Solubility of Poorly Soluble Drug - The present invention relates to solubility improving preparation for enhancing the oral absorption of a poorly soluble drug, which is comprising (A) and (B);
| 2013-08-08 |
20130203724 | Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof - The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog. | 2013-08-08 |
20130203725 | METHOD TO TREAT SMALL CELL LUNG CANCER - A method for treatment of small cell lung cancer (SCLC) that does not respond to first-line treatment or that progresses following cessation of first-line organoplatinum chemotherapy is provided that includes the administration of picoplatin, optionally in conjunction with a regimen of best supportive care. Multiple doses of picoplatin can be administered. The picoplatin can also treat SCLC that has metastacized to the brain. | 2013-08-08 |
20130203726 | FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS - The present invention relates to the use of inhibitors of FtsZ, an ancestral tubulin of prokaryotes, to restore susceptibility to β-lactam antibiotics, including carbapenems and cephalosporins, particularly in methicillin-resistant | 2013-08-08 |
20130203727 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS - The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I). | 2013-08-08 |